Description

Anastracare 1mg Anastrozole — Aromatase Inhibitor for Research

Anastracare 1mg Anastrozole is a third-generation, non-steroidal, selective aromatase inhibitor that reversibly inhibits CYP19A1 (aromatase), reducing peripheral estrogen synthesis by >95%. It is used in breast cancer research, hormone balance studies, and as a research tool to study estrogen’s roles in bone, cardiovascular, and cognitive function.

Research Applications

• Estrogen biosynthesis and aromatase pharmacology
• Breast cancer and hormone-receptor biology
• Bone mineral density and estrogen dependency
• Male hypogonadism and fertility research
• Post-cycle therapy research

Specifications

• Anastrozole 1mg per tablet | Half-life: ~50 hours
• Pharmaceutical-grade quality

For research purposes only. Not for human consumption.